Over 90 Total Lots Up For Auction at One Location - WA 04/08

This year's European Association of Nuclear Medicine congress

by Philip F. Jacobus, CEO | October 17, 2018
This year's EANM congress was held in Dusseldorf, Germany. My unofficial view is that attendance was way up. There were the usual exhibitors but the hall and the lectures seemed more crowded than they had been in previous years.

There is growing interest in molecular imaging in Western and Eastern Europe.

One thing that stood out is theranostics, which is using radioactive material to both diagnose and treat cancer. The lectures on this topic were standing room only.

For instance, rubidium with its 60 minute half-life together with PSMA identifies the cancer in the prostate. In theranostics, lutetium with its three-day half life together with PSMA comes to rest within the tumor and kills the prostate cancer.

WOW!

This was a topic a SNMMI and covered even more at EANM.

To my knowledge, the applications are limited today for theranostics but I expect them to grow.

We have written about theranostics quite a bit in recent months, here are links to a few stories in case your curious to learn more:

View all The Jacobus Report Blog Posts


About Phil Jacobus

Phil Jacobus has been involved in health care since 1977, when he visited China to sell equipment. He has done business in 35 countries and still travels extensively. Phil is active in charity, helps rural clinics and always tries to help DOTmed users when he can.

Phil is a member of AHRA, HFMA, AAMI and the Cryogenic Society of America. He has contributed to a number of magazines and journals and has addressed trade groups.

Phil's proudest achievement is that he has been happily married to his wife Barbara since 1989, who helped him found DOTmed in 1998.

You Must Be Logged In To Post A Comment